肺癌一线化疗药物不良反应及药学监护

Adverse Reactions and Pharmaceutical Care of First Line Chemotherapy of Lung Cancer

目的:总结肺癌一线化疗药物主要不良反应,探索药学监护策略,减少肺癌化疗药物不良反应的发生。方法:根据NCCN指南和临床用药情况总结肺癌一线化疗常用化疗药物,然后通过查阅药品说明书及PUBMED、CNKI数据库相关文献,结合临床实践总结肺癌一线化疗药物主要不良反应及药学监护策略。结果和结论:以铂类为基础,联合紫杉醇类、长春碱、长春瑞滨、伊立替康、依托泊苷、吉西他滨、培美曲塞的两药联合方案是肺癌化疗的标准一线方案。但化疗药物的不良反应十分突出。加强宣教,规范使用化疗药物,加强化疗过程中的监护,可减少药物不良反应的发生。

Objective To summarize the main adverse reactions of first-line chemotherapy drugs in lung cancer, and explore the strategies ofpharmaceutical care to reduce the incidence of drug adverse reactions. Methods： Summarize the chemotherapy drugs commonly used in lung cancerfirst-line therapy, according to the NCCN guidelines and clinical medication. Then summarize the drug adverse reactions and pharmaceutical carestrategies through searching for drug instructions, PUBMED and CNKI, combining with clinical practice. Results and Conclusion： Platinum-basedtwo drug regimens, such as platinum combined with taxanes, vinblastine, vinorelbine, irinotecan, etoposide, gemcitabine or pemetrexed are preferredto be first-line chemotherapy for lung cancer. But the adverse reactions of chemotherapy drugs are very prominent. Strengthening the propagandaand education, regulating the use of chemotherapy drugs, and strengthening the monitoring during chemotherapy, can reduce the occurrence of drugadverse reactions.